Pre-Filled Syringes: World Market Outlook 2011-2021


June 21, 2011
197 Pages - SKU: VSG6468316
License type:
Table of Contents Related Reports
Pre-Filled Syringes: World Market Outlook 2011-2021

  enlarge


How will the pre-filled syringes market develop this decade? Our new report shows you potential revenues to 2021 for that technology and its applications, discussing opportunities and prospects.

Our report covers pre-filled syringes in therapeutic applications: devices and drugs. Through our research and analysis we aim to save you time and help in your decisions.

You will find potential revenues for pre-filled syringe technologies at total world, submarket and national levels to 2021. What technologies and applications will expand that market? You will find predictions and answers in our report, including forecasted sales by unit.

We forecast revenues for pre-filled syringe devices, pen systems and autoinjectors. You will see how those products are changing the market and where technologies are heading.

You will also discover commercial prospects for pre-filled applications, including forecasted revenues for leading injectable drugs and their product classes:
  • Monoclonal antibodies
  • Insulins
  • Erythropoietin products
  • Interferons
  • Granular-colony stimulating factors (G-CSF)
  • Recombinant coagulation factors
  • Vaccines
  • Biosimilars.
In particular, you will find discussions of Abbott Laboratories, Becton, Dickinson and Company, Vetter Pharma-Fertigung, SCHOTT, Ypsomed, Gerresheimer and MGlas.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Original analysis with revenues, growth rates, market shares, opinion and discussions

You will find revenue forecasts, growth rates, market shares, a SWOT/STEP review, opinions from our survey and discussions of technologies and companies. We provide 120 tables and charts and three research interviews (shown in the accompanying lists).

Pre-Filled Syringes: World Market Outlook 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:
  • You will discover revenue forecasts to 2021 for the world pre-filled syringes market and its main components, seeing where revenue growth will occur
  • You will see a forecast of pre-filled syringe unit sales at world level
  • You will find revenue predictions to 2021 for technologies, with discussions
  • You will discover revenue forecasts to 2021 for injectable drug classes
  • You will receive revenue forecasts to 2021 for leading injectable drugs - Lantus, Novorapid, Humalog, Humira, Enbrel, Neulasta, Avonex, Rebif and others
  • You will find revenue forecasts to 2021 for leading national markets - US, Japan, UK, Germany, France, Spain, Italy, China and India - seeing growth trends
  • You will assess leading companies for pre-filled syringes, analysing their activities, R&D and commercial outlooks
  • You will examine established and emerging pre-filled drug technologies, seeing where the industry is heading
  • You will investigate competition and opportunities influencing the industry and market from 2011 onwards
  • You will see what will stimulate and restrain the industry and market from 2011
  • You will analyse opportunities and challenges for established companies and those seeking to enter the pre-filled syringe market
  • You will receive three interviews with authorities on pre-filled syringe technologies.
That mix of quantitative and qualitative analysis sets our report apart. We tackle crucial questions in the pre-filled syringes industry and market, aiming to benefit your work.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


Additional Information


Report Excerpt

5.3 Byetta/Exenatide LAR: Non-Insulin Revolutionary Injectable

Eli Lilly/Amylin's GLP-1 agonist anti-diabetic drug Byetta (exenatide) is available for subcutaneous injection as a solution in a glass cartridge that has been assembled in a pen-injector format. Byetta pre-filled pen is available as either 5ìg or 10ìg exenatide per dose. Byetta enjoyed marked success in 2007, where its sales grew by 51% over the previous year, reaching a total of $0.650bn. For the year extending through the second quarter of 2008, Byetta generated sales of $0.669bn, with a growth of 30%. It has continued to enjoy high growth and generated sales revenues of $0.797 billion for the whole of 2009, which was a growth of 6% from the previous year. In 2010, the worldwide sales of Byetta reached $0.710bn and visiongain predicts sales to reach $1.00bn by 2015 and $1.28 billion by 2021 (Tables 5.14-5.15 and Figure 5.7). With the withdrawal of rosiglitazone from EU markets, Byetta will perform well until pipeline drugs enter the market, improving diabetes treatment. Sales will rise with the entry of Byetta/Exenatide LAR to the market.

Companies Listed

Abbott Laboratories
Albert David
Alkermes
Alshifa Medical Syringes Manufacturing Company
Althea Technologies
Amgen
Amylin Pharmaceuticals
Astellas Pharma
AstraZeneca
Avitro
B. Braun Medical
Battelle Medical Device Solutions
Baxter International
Bayer
BD Biosciences
BD Healthcare Consulting & Services (BDHCS)
BD Pharmaceutical Systems
Becton, Dickinson and Company
Berna Biotech
Biogen Idec
Bioject Medical Technologies
Biopartners
Boston Scientific Corp.
C. R. Bard.
Cambridge Antibody Technology (now a part of AstraZeneca)
Cambridge Consultants
Catalent Pharma Solutions
Centers for Disease Control and Prevention (CDC) [US]
Centocor Ortho Biotech
Chugai Pharmaceutical (a subsidiary of Roche Holding AG.)
Coeur
Covidien
CSL Behring
CSL Biotherapies
CT Arzneimettel
Daikyo Seiko
Disetronic Group
Disetronic Holding
Dong-A
Dongbao
Eisai
Eli Lilly
E. R. Squibb & Sons
European Medicines Agency (EMEA/EMA)
European Society for Medical Oncology
Flamel Technologies
Food and Drug Administration (FDA) [US]
Gate Pharmaceuticals
Genentech
GeneScience Pharmaceutical Co.
Genzyme
Gerresheimer
GlaxoSmithKline
Henke-Sass Wolf
Hindustan Syringes and Medical Devices
Hi-Tech Medical Products
Hospira
Human Genome Sciences
Hyaluron Contract Manufacturing
Immunex
Insulet Corp
International Medication Systems
Johnson & Johnson
LG Life Sciences
Life-Shield Products
Medex
Merck & Co.
Merck Serono
Merit Medical Systems
MG Sterile Products
MGlas
Milestone Scientific
Ministry for Health, Labor and Welfare [Japan]
National Health Service (NHS) [UK]
Novartis
Novo Nordisk
Nycomed
Occupational Safety and Health Administration (OSHA) [US]
Organon Teknika
Otsuka Pharmaceutical
Owen Mumford
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Plas-Pak Industries
PRC State Food and Drug Administration [China]
Protalix Biotherapeutics
Ratiopharm
Retractable Technologies
Revolutions Medical Corporation
Roche
Royal College of Nursing (RCN) [UK]
Safety Syringes
Sandoz
Sanofi Pasteur
Sanofi (previously sanofi-aventis)
Schering-Plough
SCHOTT
Shanghai Celgen Bio-Pharmaceutical Co.
Simponi
Smiths Medical International
Specialised Health Products International
Star Syringe
State Food and Drug Administration [China]
Takeda Pharmaceutical Company
Talecris Biotherapeutics
Terumo Medical Corporation
Teva Pharmaceutical Industries
The Research Foundation for Microbial Diseases of Osaka University (BIKEN)
Tonghua Dongbao Pharmaceutical Co.
UCB
UltiMed
Unilife Medical Solutions
Vetter Pharma International
Vetter Pharma-Fertigung
Vita Needle Company
West Pharmaceutical Services
World Health Organization (WHO)
Wuxi Yushou Medical Appliances Co.
Wyeth (now part of Pfizer)
Ypsomed

More Drug Delivery reports by Visiongain

Drug Delivery Technologies: Commercial Prospects 2012-2022 by Visiongain
How to find industry trends and revenue prospects there What does the future hold for drug delivery technologies? Visiongain's report shows you potential ...
World Diabetes Drug Market 2011-2021 by Visiongain
Where will revenue growth occur in the diabetes treatment market? Our new report shows you the potential that drug market offers from 2011 to 2021, ...
See all reports like this >>

 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Drug Delivery Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!